Health Economics & Outcomes Research

Zowall H, Brewer C, Deutsch A. Modeling of Risks and Benefits of Lung Cancer Screening Strategies using Low-Dose Helical CT (LDCT) Technology in Canada. Value in Health 11/2015; 18(7), A372–A373. (Download PDF - 1,129KB)

Zowall H, Brewer C, Deutsch A. Projected Cost Savings of Introducing Fecal Microbiota Transplant Treatment for Clostridium Difficile Infection in Canada. Value in Health 05/2015; 18(3):A238. (Download PDF - 1,051KB)

Zowall H, Brewer C, Deutsch A. Cost-Effectiveness of Fecal Microbiota Transplant in Treating Clostridium Difficile Infection in Canada. Value in Health 11/2014; 17(7):A676. (Download PDF - 61KB)

Zowall H, Brewer C, Deutsch A. A model of clostridium difficile infection: dynamic transmission between hospitals, long-term care facilities and communities. Value in Health 05/2014; 17(3):A280-A281. (Download PDF - 112KB)

Zowall H, Brewer C, Deutsch A. An online patient-oriented radiation risk assessment tool to project cancer risk following exposure to low ionizing radiation in Canada. Value in Health 05/2014; 17(3):A100. (Download PDF - 144KB)

Zowall H, Brewer C, Deutsch A. A comparison of medical computed tomographic utilization and potential related cancer risks in the United States and in Canada. Value in Health Vol. 16, 2013 May, Issue 3, Page A150. (Download PDF - 65KB)

Zowall H, Brewer C, Deutsch A. Trends in Computed Tomography Use in Canada: Low-Dose Ionizing Radiation and the Potential Related Cancer Risk. Value in Health Vol. 15, 2012 November, Issue 7, Page A436. (Download PDF - 69KB)

Zowall H, Brewer C, Deutsch A. Managing the Risk of Exposure to Low-Ionizing Radiation in Canada: A Population Model. Value in Health Vol. 15, 2012 June, Issue 4, Page A233. (Download PDF - 67KB)

Zowall H, Brewer C, Deutsch A. Public Funding for Infertility Treatments in Canada: Eligibility and Demand for IVF in Canada. Value in Health Vol. 15, 2012 June, Issue 4, Page A196. (Download PDF - 68KB)

Zowall H, Brewer C. Are Older Mothers More prone to Having Children with Disabilities? Lifetime Disability Outcomes Versus Multiple Birth Reductions Arising from In-Vitro Fertilization (IVF) Treatments in Canada. Value in Health Vol. 14, 2011 November, Issue 7, Page A408. (Download PDF - 57KB)

Zowall H, Brewer C. The impact of long-term disability costs arising from in-vitro fertilization (IVF) treatment: the cost-effectiveness analysis of reducing multiple births. Value in Health Vol. 14, 2011 May, Issue 3, Page A108. (Download PDF - 57KB)

Zowall H, Brewer C. Cost-effectiveness of reducing multiple births: in-vitro fertilization strategies in Canada. Value in Health Vol. 12, 2009 October, Issue 7, Page A292. (Download PDF - 80KB)

Zowall H, Cairns JA, Brewer C, Lamping DL, Gedroyc WMW, Regan L. Cost-effectiveness of magnetic resonance-guided ultrasound surgery for treatment of uterine fibroids. BJOG 2008 April; Volume 115, Issue 5, 653-662. (Download PDF - 231KB)

Moe Gordon W, Howlett Jonathan, Januzzi James L, Zowall H, N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure. Circulation. 2007;115:3103-3110. (Download PDF - 314KB)

Grover SA, Coupal L, Zowall H. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors. What are the benefits of avoiding blood pressure destabilization? Hypertension. 2005;45:92. (Download PDF - 231KB)

Beck EJ, Gaudreault M, Brewer C, Mandalia S, Zowall H, Gilmore N, Klein M, Lalonde R, Murphy T, Piche, A, Roy J, de la Sablonniere, Hankins C. Cost-effectiveness of HAART, Canada , 1991-2001. AIDS. 2004 Dec 3;18(18):2411-8. (Download PDF - 118KB).

Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med 2003;163:333-339. (Download PDF - 96KB)

Grover SA, Coupal L, Zowall H, Weiss TW, Alexander CM. Evaluating the benefits of treating dyslipidemia among Americans: the importance of diabetes as a risk factor. Am J Med 2003;115:122-128.

Zowall H, Grover SA. Costs of dyslipidemia. Expert Review of Pharmacoeconomics & Outcomes Research 2003;3(3):273-81. (Download PDF - 203KB)

Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DRJ. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50. (Download PDF - 1200KB)

Gilmore N, Zowall H. Threatening inequality: the struggle to maintain Canada’s national healthcare system. The London Journal of Canadian Studies 2001/2002, volume 17, 12-39. The London Conference for Canadian Studies.

Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:977-83. (Download PDF - 243KB)

Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:987-92. (Download PDF - 218KB)

Grover SA, Dorais M, Paradis G, Fodor JG, Frohlich JJ, McPherson R, Coupal L, Zowall H. Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. Can Med Assoc J 2000;163:1263-9.

Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulmonary Rehabil 2000;20:147-155.

Grover SA, Coupal L, Zowall H, Marc Dorais. The cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000;102:722-727. (Download PDF - 70KB)

Grover SA, Zowall H, Coupal L, Krahn MD. Prostate cancer: 12. The economic burden. Can Med Assoc J 1999;160:685-690.

Grover SA, Coupal L, Paquet S, Zowall H. The cost-effectiveness of HMG-CoA reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600. (Download PDF - 102KB)

Clarke AE, Levinton C, Joseph L, Penrod J, Zowall H, Sibley JT, Grover SA, Esdaile JM. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. J Rheumatol 1999;26:1068-1075.

Grover SA, Zowall H, Coupal L, Krahn MD. Chapter 12. The economic burden. In: NA Iscoe , MAS Jewett (eds). Prostate cancer: balancing the risks in diagnosis and treatment. Canadian Medical Association, 1999.

Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of
modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-662. (Download PDF - 284KB)

Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, Shiroky J, Neville C, Lubeck DP, Grover SA, Esdaile JM. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: A twelve year study. J Rheumotol 1997;24(6):1051-1060.

Hamilton V, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of raising HDL. JAMA 1995;273(13):1032-1038. (Download PDF - 452KB)

Gilmore N, Grover SA, Zowall H, Fraser RD, Deutsch A, Coupal L. Modeling health care costs attributable to HIV infection and coronary heart disease in immigrants to Canada. In: EH Kaplan, M Brandeau (eds). Modeling the AIDS Epidemic: Planning, Policy, and Prediction. New York: Raven Press, 1994.

Zowall H, Coupal L, Gilmore N, Fraser R, Deutsch A, Grover SA. Economic impact of HIV infection and coronary heart disease in immigrants to Canada. Can Med Assoc J 1992;147(8):1163-1172.

Zowall H, Fraser R, Gilmore N, Deutsch A, Grover SA. HIV antibody screening among immigrants: A cost/benefit analysis. Can Med Assoc J 1990;143(2):101-107.

ZOWALL CONSULTING HEALTH ECONOMICS & OUTCOMES RESEARCH